Sleep research article
The effects of cognitive behavioral therapy for insomnia on cardiovascular and immunological outcomes: A randomized-controlled study.
Authors: Reyt M , Jarrin DC , Perrault AA , Borgetto F , Smith D , Gong K , Tarelli L , Savard J , Dang-Vu TT , Gouin JP
One-line summary
A sleep science research article on The effects of cognitive behavioral therapy for insomnia on cardiovascular and immunological outcomes: A randomized-controlled study..
Sleep health notes
Sleep health notes will be added by the Sleepatch editorial team.
中文解读
中文解读待补充：本站会优先为失眠研究、睡眠质量改善、昼夜节律等高价值睡眠研究添加中文说明。
Original abstract
Insomnia disorder is associated with pathophysiological alterations that may contribute to long-term mental and physical health risks. Cognitive behavioral therapy for insomnia (CBTi) is the first-line treatment for insomnia disorder, yet its effects on physiological outcomes remain unclear. This secondary analysis of a randomized-controlled trial examined the effects of CBTi on cardiovascular and immunological biomarkers. Sixty-two participants with insomnia disorder were randomized to CBTi (N = 33, 75.8% female, M<sub>age</sub> = 48.8 ± 17.1 years) or Waitlist (WL) control (N = 29, 75.9% female, M<sub>age</sub> = 52.2 ± 15.6 years). Cardiovascular parameters included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and nocturnal heart rate variability (HRV). Inflammatory markers from blood samples included C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and brain-derived neurotrophic factor (BDNF). All outcomes were assessed at baseline (T1), at 3 months following completion of CBTi or WL period (T2), and at 6 months for the WL group (T3, after CBTi for the WL participants). No significant Group-by-time effects were observed for SBP, DBP, HR, HRV and any inflammatory markers (p<sub>s</sub> > 0.05) from T1 to T2. When pooling treatment effects following CBTi exposure across both groups (T1 to T2 in CBTi group and T1 to T3 in WL group), no significant biomarker changes were observed. Overall, results indicate that CBTi did not produce detectable changes in cardiovascular or inflammatory markers among healthy individuals with insomnia disorder. These findings suggest a dissociation between improved subjective insomnia symptoms and the lack of change in cardiovascular and immune biomarkers following CBTi in healthy participants (https://www.isrctn.com/ISRCTN13983243).
Links and sources
This content is provided for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Sleep disorders, chronic insomnia, sleep apnea, and other conditions must be evaluated and treated by a qualified healthcare professional. If you experience persistent or severe sleep problems, consult a licensed physician or sleep specialist. Research cited refers to peer-reviewed studies; individual results may vary. Sleepatch does not endorse any specific medication, supplement, or therapy.
Want a personalized sleep improvement plan?
Sleepatch can prepare a customized sleep wellness program, insomnia relief guide, and evidence-based sleep coaching based on your needs.
Explore sleep services
Comments